
3.06 Delayed Data As of May 27 | ![]() Today’s Change | 2.66 Today|||52-Week Range 11.95 | -32.89% Year-to-Date |
The 6 analysts offering 12-month price forecasts for Innate Pharma SA have a median target of 10.40, with a high estimate of 12.65 and a low estimate of 7.69. The median estimate represents a +239.95% increase from the last price of 3.06.
The current consensus among 6 polled investment analysts is to Buy stock in Innate Pharma SA. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.